[go: up one dir, main page]

AR050254A1 - Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas - Google Patents

Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas

Info

Publication number
AR050254A1
AR050254A1 ARP050102669A ARP050102669A AR050254A1 AR 050254 A1 AR050254 A1 AR 050254A1 AR P050102669 A ARP050102669 A AR P050102669A AR P050102669 A ARP050102669 A AR P050102669A AR 050254 A1 AR050254 A1 AR 050254A1
Authority
AR
Argentina
Prior art keywords
intermediaries
pirrolotriazines
prepare
manufacture
processes
Prior art date
Application number
ARP050102669A
Other languages
English (en)
Inventor
Gerard Crispino
Junying Fan
Zhen-Wei Cai
Stephanie Barbosa
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR050254A1 publication Critical patent/AR050254A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)

Abstract

Reivindicacion 1: Un compuesto que tiene la formula (1), caracterizado porque Ra y Rb son metilo, etilo o propilo.
ARP050102669A 2004-06-28 2005-06-28 Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas AR050254A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58345904P 2004-06-28 2004-06-28
US61256304P 2004-09-23 2004-09-23

Publications (1)

Publication Number Publication Date
AR050254A1 true AR050254A1 (es) 2006-10-11

Family

ID=35457856

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050102668A AR049536A1 (es) 2004-06-28 2005-06-28 Compuestos heterociclicos condensados con actividad inhibitoria de la proteina tirosina cinasa; una composicion farmaceutica que los contiene como principio activo y su utilizacion en el tratamiento del cancer.
ARP050102669A AR050254A1 (es) 2004-06-28 2005-06-28 Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050102668A AR049536A1 (es) 2004-06-28 2005-06-28 Compuestos heterociclicos condensados con actividad inhibitoria de la proteina tirosina cinasa; una composicion farmaceutica que los contiene como principio activo y su utilizacion en el tratamiento del cancer.

Country Status (14)

Country Link
US (2) US7173031B2 (es)
EP (3) EP1761268A4 (es)
JP (3) JP4860609B2 (es)
KR (3) KR20070028458A (es)
AR (2) AR049536A1 (es)
AU (2) AU2005260056B2 (es)
BR (1) BRPI0512722A (es)
CA (1) CA2571680A1 (es)
IL (1) IL180325A0 (es)
MX (2) MXPA06015032A (es)
NO (3) NO20070453L (es)
PE (2) PE20060374A1 (es)
TW (2) TW200607505A (es)
WO (3) WO2006004636A2 (es)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US9169406B2 (en) * 2003-08-25 2015-10-27 Dow Global Technologies Llc Coating compositions
PT2210607E (pt) * 2003-09-26 2012-01-31 Exelixis Inc N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolina-4-ilpropil)oxi]quinolina-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida para o tratamento do cancro
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
AU2005217328B2 (en) 2004-02-27 2007-10-04 Eisai R & D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (2)
EP2786995A1 (en) * 2004-03-30 2014-10-08 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7977345B2 (en) * 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
MX2007001216A (es) * 2004-07-30 2007-03-23 Methylgene Inc Inhibidores de la senalizacion del receptor del factor de crecimiento endotelial vascular y del receptor del factor de crecimiento del hepatocito.
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US8875040B2 (en) * 2005-06-07 2014-10-28 Rockwell Automation Technologies, Inc. Universal web-based reprogramming method and system
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
US7470693B2 (en) * 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
DK1904504T3 (da) * 2005-05-20 2014-06-23 Methylgene Inc Inhibitorer af vegf-receptor- og hgf-receptorsignalering
JP5148499B2 (ja) * 2005-05-20 2013-02-20 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
US7232901B2 (en) 2005-07-01 2007-06-19 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7402582B2 (en) * 2005-07-01 2008-07-22 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
EP1921078B1 (en) 2005-08-05 2013-01-09 Chugai Seiyaku Kabushiki Kaisha Multikinase inhibitor
CN101198590B (zh) 2005-08-24 2012-05-09 卫材R&D管理有限公司 吡啶衍生物及嘧啶衍生物（3）
US7732613B2 (en) * 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
US7348325B2 (en) * 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2635888A1 (en) * 2006-01-04 2007-07-19 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2001880A2 (en) 2006-03-07 2008-12-17 Array Biopharma, Inc. Heterobicyclic pyrazole compounds and methods of use
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
SI2010538T1 (sl) * 2006-04-21 2013-06-28 Bristol-Myers Squibb Comapany POSTOPEK ZA PRIPRAVO ((1R),2S)-2-AMINOPROPIONSKE KISLINE-2-(4-(4- FLUOR-2-METIL-1H-INDOL-5-ILOKSI)-5-METILPIROL)2,1-f-(1,2,4-TRIAZIN- 6-ILOKSI)-1-METILETIL ESTRA
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
EP2023926B1 (en) * 2006-05-19 2011-10-12 Bayer Pharma Aktiengesellschaft Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
WO2007146824A2 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
US8778977B2 (en) 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
CA2661333C (en) 2006-08-23 2014-08-05 Eisai R&D Management Co., Ltd. Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
WO2008046216A1 (en) * 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
JP2010507618A (ja) * 2006-10-27 2010-03-11 グラクソ グループ リミテッド ｃ−Ｍｅｔキナーゼ阻害薬としての７−アザインドール誘導体
CA2669266C (en) * 2006-11-08 2014-04-29 Bristol-Myers Squibb Company Pyridinone compounds
US8188272B2 (en) 2007-03-21 2012-05-29 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2008293038B2 (en) 2007-08-29 2013-08-29 Mirati Therapeutics, Inc. Inhibitors of protein tyrosine kinase activity
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
TW200924770A (en) 2007-11-06 2009-06-16 Astrazeneca Ab Novel compounds 089
WO2009061516A1 (en) 2007-11-08 2009-05-14 New York University School Of Medicine Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
ES2531396T3 (es) 2008-01-23 2015-03-13 Bristol Myers Squibb Co Proceso para preparar compuestos de piridinona
JP5314050B2 (ja) 2008-01-23 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ４−ピリジノン化合物および癌についてのその使用
NZ589336A (en) * 2008-03-05 2011-12-22 Methylgene Inc Pyridine derivatives as inhibitors of protein tyrosine kinase activity
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
UY31984A (es) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
UY31982A (es) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2011022028A2 (en) * 2009-05-18 2011-02-24 Tufts University Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof
PT2442809T (pt) 2009-06-17 2016-12-06 Vertex Pharma Inibidores da replicação de vírus da gripe
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010289143A1 (en) 2009-08-24 2012-02-16 Ascepion Pharmaceuticals, Inc. 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
EP2563773A1 (en) 2010-04-29 2013-03-06 Deciphera Pharmaceuticals, LLC Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
NZ703111A (en) 2010-05-17 2016-07-29 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
JP5898074B2 (ja) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013022519A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
AU2013239398B2 (en) 2012-03-30 2017-09-07 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5- disubstituted -3H-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of C-met protein kinases
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
WO2014115171A1 (en) * 2013-01-24 2014-07-31 Council Of Scientific & Industrial Research Triazine compounds and a process for preparation thereof
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3409674T (pt) 2013-10-17 2022-07-18 Blueprint Medicines Corp Processo para preparar composições úteis para tratar distúrbios relacionados com kit
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
DK3087070T3 (en) * 2013-12-26 2017-12-04 Ignyta Inc PYRAZOLO [1,5-A] PYRIDINE DERIVATIVES AND PROCEDURES FOR THEIR USE
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN106046007B (zh) 2015-04-07 2019-02-05 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP3521276B1 (en) 2016-09-30 2021-03-10 Guangdong Raynovent Biotech Co., Ltd. Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
CN110072865B (zh) * 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
CA3053739C (en) 2017-02-15 2023-02-14 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
WO2018228923A1 (en) * 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
US11427578B1 (en) 2017-07-18 2022-08-30 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
US11168093B2 (en) 2018-12-21 2021-11-09 Celgene Corporation Thienopyridine inhibitors of RIPK2
TWI845657B (zh) 2019-04-12 2024-06-21 美商纜圖藥品公司 (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙-1-胺之晶形及其製造方法
CA3136802A1 (en) 2019-04-12 2020-10-15 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
CN110407839B (zh) * 2019-07-01 2022-01-04 江西科技师范大学 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
WO2021020362A1 (ja) 2019-07-29 2021-02-04 武田薬品工業株式会社 複素環化合物
CN115103834A (zh) * 2020-02-14 2022-09-23 大鹏药品工业株式会社 酰硫脲化合物的类缘物质
CN113880845A (zh) * 2021-10-13 2022-01-04 广州六顺生物科技股份有限公司 吡咯并三嗪衍生物及其制备方法和应用
WO2023111996A1 (en) * 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
WO2024182556A1 (en) 2023-02-28 2024-09-06 Reglagene, Inc. Compositions and methods for making and using small molecules for the treatment of health conditions

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646202A (en) 1967-11-22 1972-02-29 Merck & Co Inc Liver fluke compositions containing salicylic acid derivatives
JPS54115384A (en) 1978-02-28 1979-09-07 Hokko Chem Ind Co Ltd Ryrazolyl pyrimidine derivative, and agricultural and horticultural fungicides
CH648611A5 (de) 1980-08-18 1985-03-29 Staeubli Ag Verfahren und schaftmaschine zur gleichstellung aller schaefte einer webmaschine.
GB2106500B (en) 1981-09-18 1986-01-02 Dow Chemical Co Method for making benzoylphenylureas
DE3139457A1 (de) 1981-10-03 1983-04-21 Bayer Ag, 5090 Leverkusen Neue substituierte benzanilidether, verfahren zu ihrer herstellung, ihre verwendung als fungizide und zwischenprodukte hierfuer
DE3464368D1 (de) 1983-03-09 1987-07-30 Beecham Group Plc Anti-inflammatory pyrazolo pyridines
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
US4663341A (en) 1984-02-16 1987-05-05 Rohm And Haas Company Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides
GB8404584D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
CH657015A5 (de) 1984-06-27 1986-08-15 Ciba Geigy Ag Motten- und kaeferschutzmittel.
JPS6133176A (ja) 1984-07-24 1986-02-17 Ishihara Sangyo Kaisha Ltd Ｎ−ニトロベンゾイル−ｎ’−ピリダジニルオキシフエニルウレア系化合物、それらの製造方法及びそれらを含有する抗癌剤
US4753940A (en) * 1985-02-15 1988-06-28 Ciba-Geigy Corporation Barbituric acid derivatives
JPS62135463A (ja) 1985-12-09 1987-06-18 Ishihara Sangyo Kaisha Ltd Ｎ−ベンゾイルウレア系化合物、それらを含有する抗癌剤並びにそれらの製造方法
JPS625959A (ja) 1986-03-05 1987-01-12 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物
JPS6262A (ja) 1986-03-05 1987-01-06 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物の製造方法
JPS625960A (ja) 1986-03-05 1987-01-12 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物の製造方法
US4908056A (en) 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
DE3830054A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
EP0420804A3 (en) 1989-09-26 1991-11-27 Ciba-Geigy Ag Anthelmintic compounds
SU1761753A1 (ru) 1990-07-16 1992-09-15 Ф. С. Михайлицын и Н. С. Уварова 5-(2-Хлор-4-нитро(амино)фенокси) бензо-2,1,3-тиадиазол в качестве промежуточного соединени в синтезе 5- @ 2-хлор-4-[(2-окси-3,5-дибромбензоил)амино]фенокси @ бензо-2,1,3-тиадиазола, про вл ющего активность при гименолепидозе белых мышей
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
WO1997016452A1 (en) * 1995-11-01 1997-05-09 Novartis Ag Purine derivatives and processes for their preparation
WO1997017329A1 (fr) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant
DE19710609A1 (de) 1997-03-14 1998-09-17 Bayer Ag Substituierte Aminosalicylsäureamide
CA2294117A1 (en) 1997-07-03 1999-01-14 Dupont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
EA005889B1 (ru) * 1997-11-11 2005-06-30 Пфайзер Продактс Инк. Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
US6362369B2 (en) 1997-11-25 2002-03-26 Nihon Nohyaku Co., Ltd. Phthalic acid diamide derivatives fluorine-containing aniline compounds as starting material, agricultural and horticultural insecticides, and a method for application of the insecticides
TW515786B (en) 1997-11-25 2003-01-01 Nihon Nohyaku Co Ltd Phthalic acid diamide derivatives, agricultural and horticultural insecticides, and a method for application of the insecticides
ATE413386T1 (de) 1998-01-29 2008-11-15 Amgen Inc Ppar-gamma modulatoren
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ299375B6 (cs) 1998-11-30 2008-07-09 Nihon Nohyaku Co., Ltd. Ftalamidové deriváty nebo jejich soli, zemedelsko-zahradnický insekticid je obsahující a jeho použití
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
CN1183114C (zh) 1999-01-22 2005-01-05 麒麟麦酒株式会社 喹啉衍生物及喹唑啉衍生物
PL212545B1 (pl) 1999-02-22 2012-10-31 Biotechnolog Forschung Gmbh Modyfikowane epofilony C-21 o wzorze Ia lub Ib oraz sposób wytwarzania zwiazku o wzorze 9
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
EP1183033B1 (en) 1999-05-21 2006-03-01 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2003528806A (ja) 1999-07-20 2003-09-30 ダウ・アグロサイエンス・エル・エル・シー 殺菌・殺カビ性複素環式芳香族アミドおよびそれらの組成物、使用および製造方法
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
HUP0300059A3 (en) 1999-09-21 2003-08-28 Astrazeneca Ab Quinazoline derivatives, process for their preparation, pharmaceutical compositions containing the compounds and use of the new and known quinazoline derivatives against proliferative disease
DE60018769T2 (de) 1999-09-24 2005-08-04 Nihon Nohyaku Co., Ltd. Aromatische diamid-derivate oder ihre salze, chemikalien für die landwirtschaft/den gartenbau und verfahren zu ihrer anwendung
WO2001042243A2 (en) 1999-12-08 2001-06-14 Advanced Medicine, Inc. Protein kinase inhibitors
EP1243582A4 (en) 1999-12-24 2003-06-04 Kirin Brewery QUINOLINE, QUINAZOLINE DERIVATIVES, AND MEDICINES CONTAINING SUCH SUBSTANCES
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
EP1287001B1 (en) 2000-06-06 2004-09-29 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
KR100589032B1 (ko) * 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
AU3276002A (en) 2000-11-17 2002-05-27 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US7238813B2 (en) 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
US6960580B2 (en) * 2001-03-08 2005-11-01 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic substituted quinoline compounds
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
US7425564B2 (en) 2001-06-22 2008-09-16 Kirin Beer Kabushiki Kaisha Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same
SE0102384D0 (sv) * 2001-07-03 2001-07-03 Pharmacia Ab New compounds
AU2002323743A1 (en) 2001-08-01 2003-02-17 Nissan Chemical Industries, Ltd. Substituted amides and pest controllers
US7495104B2 (en) 2001-10-17 2009-02-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
AU2002344567A1 (en) 2001-11-28 2003-06-10 Daiso Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
CA2468463C (en) 2001-12-03 2013-06-18 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2003221753A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
PT1497019E (pt) 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
US7388009B2 (en) 2002-04-23 2008-06-17 Bristol-Myers Squibb Company Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TWI272271B (en) * 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
EP1543009A4 (en) 2002-08-02 2007-08-08 Bristol Myers Squibb Co Pyrrolotriazine KINASE INHIBITORS
PL378121A1 (pl) 2003-02-05 2006-03-06 Bristol-Myers Squibb Company Sposób wytwarzania pirolotriazynowych inhibitorów kinazy
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds

Also Published As

Publication number Publication date
KR20070026621A (ko) 2007-03-08
AU2005259894C1 (en) 2009-09-17
TW200604184A (en) 2006-02-01
JP2008504368A (ja) 2008-02-14
WO2006004636A3 (en) 2006-05-26
PE20060374A1 (es) 2006-05-07
US20060004006A1 (en) 2006-01-05
AR049536A1 (es) 2006-08-09
EP1761268A2 (en) 2007-03-14
JP4782117B2 (ja) 2011-09-28
NO20070514L (no) 2007-03-12
MXPA06015192A (es) 2007-02-28
KR20070028458A (ko) 2007-03-12
AU2005259894A1 (en) 2006-01-12
EP1761268A4 (en) 2009-07-08
WO2006004833A3 (en) 2006-07-13
EP1771177A2 (en) 2007-04-11
JP2008504366A (ja) 2008-02-14
PE20060524A1 (es) 2006-06-21
TW200607505A (en) 2006-03-01
BRPI0512722A (pt) 2008-04-01
EP1768983A2 (en) 2007-04-04
WO2006004884A2 (en) 2006-01-12
WO2006004833A2 (en) 2006-01-12
AU2005259894B2 (en) 2009-03-19
AU2005260056B2 (en) 2009-08-27
AU2005260056A1 (en) 2006-01-12
US7173031B2 (en) 2007-02-06
CA2571680A1 (en) 2006-01-12
IL180325A0 (en) 2007-07-04
JP2008504367A (ja) 2008-02-14
KR20070037448A (ko) 2007-04-04
NO20070506L (no) 2007-02-14
NO20070453L (no) 2007-01-24
WO2006004884A3 (en) 2006-03-23
JP4860609B2 (ja) 2012-01-25
US20050288290A1 (en) 2005-12-29
EP1771177A4 (en) 2009-07-29
MXPA06015032A (es) 2007-02-08
WO2006004636A2 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
BR0308211A (pt) Cumarinas úteis como biomarcadores
CR10157A (es) Compuestos químicos
DE60106954D1 (de) Resorcin-derivate
PA8676201A1 (es) Metodos para sintetizar 3-cianoquinolinas sustituidad y sus intermediarios
CR8451A (es) Uso de derivados de n-arilhidracina para combatir pestes
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
BRPI0606358A2 (pt) uso de pelo menos um aminoditiol, processo e kit para a deformação permanente dos cabelos e aminotióis
BRPI0606379A2 (pt) triazolftalazinas
CL2007002390A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de leucemia y discrasias hematologicas.
DE60328138D1 (de) Zwischenprodukte für die Herstellung von Dioxan-2-alkylcarbamaten
CR9495A (es) Composicion en emulsion estable
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
BRPI0514584A (pt) método para preparar irbesartan e intermediários do mesmo
GT200600010A (es) Procedimientos para la preparacion de alcoholes aminoetoxibencilicos
DE60216885D1 (de) Prozessor für die Befehlszeilenschnittstelle
UY26556A1 (es) Compuestos calcilíticos
ES1050889Y (es) Articulo para masticar
DE602004009313D1 (de) Organosiliziumverbindungen und deren verwendung
BRPI0410638A (pt) derivados de azitromicina
DE502004007109D1 (de) Turbomaschine
ES1053744Y (es) Antivibrador-amortiguador de techos para suspender la perfileria usada en falsos techos y techos flotantes.
ES1052252Y (es) Luminaria de empotrar para paredes y techos.
SE0500291L (sv) New composition and the use thereof
ITMI20042402A1 (it) Processo per la preparazione di n,n-dimetil-n'-feniluree

Legal Events

Date Code Title Description
FA Abandonment or withdrawal